Letters to the Editor

Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome

Division of Hematology, Oncology, Stem Cell Transplantation, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL
Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
Hematology/Oncology, Lucile Packard Children's Hospital, Palo Alto, California, USA; Hematology/Oncology, Stanford Cancer Institute, Palo Alto, California
Sorbonne Université, Hôpital Armand Trousseau, AP-HP, Paris
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
Department of Pediatrics, Section of Hematology/Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX
Division of Pediatrics, Leukemia Section, The University of Texas MD Anderson Cancer Center, Houston, Texas
Division of Hematology/Oncology, Seattle Children's Hospital, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Haematologica Early view Sep 3, 2026 https://doi.org/10.3324/haematol.2026.301245